Abstract
TECOS was a randomized, double-blind, placebo-controlled trial assessing the impact of sitagliptin vs. placebo on cardiovascular outcomes when added to usual care in patients with type 2 diabetes. We report the use of concomitant diabetes medications and the risk for progression to insulin during follow-up. TECOS enrolled 14 671 participants with HbA1c 6.5%-8.0% on monotherapy with metformin, pioglitazone, sulfonylurea (SU), or dual therapy with two oral agents or insulin with or without metformin. Subsequent diabetes management was by the participant's usual care physician. Time to initiation of insulin and risk of hypoglycaemia were estimated using Cox proportional hazards models. The most common glucose-lowering regimens at baseline were metformin monotherapy (30.2%), SU monotherapy (8.5%), metformin/SU therapy (35.1%), and insulin with or without metformin (13.9% and 8.6%, respectively). Over a median 3.0 years' follow-up, diabetes therapy was intensified in 25.2% of participants (sitagliptin 22.0%, placebo 28.3%). Medications most commonly added were SU (8.3%) or insulin (8.8%). Insulin initiation in the usual care setting occurred at mean (standard deviation) HbA1c of 8.5 (1.5)%. Sitagliptin did not impact rates of severe...Continue Reading
References
Jan 30, 2002·Diabetes Care·Alex WrightUNKNOWN U.K. Prospective Diabetes Study Group
Oct 16, 2004·The Journal of Clinical Endocrinology and Metabolism·Kathrin MaedlerMarc Y Donath
Dec 6, 2006·The New England Journal of Medicine·Steven E KahnUNKNOWN ADOPT Study Group
Jun 27, 2007·Diabetes, Obesity & Metabolism·K HermansenUNKNOWN Sitagliptin Study 035 Group
Jan 10, 2008·Diabetes Care·UNKNOWN American Diabetes Association
Oct 24, 2008·Diabetes Care·David M NathanUNKNOWN European Association for Study of Diabetes
Mar 3, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Ann AlbrightDesmond E Williams
Oct 27, 2009·Acta Diabetologica·María CostiAlbert Goday
Jan 23, 2010·Diabetes, Obesity & Metabolism·T VilsbøllL Katz
Jul 19, 2011·International Journal of Medical Informatics·Eva Thors Adolfsson, Andreas Rosenblad
Mar 27, 2012·Diabetes, Obesity & Metabolism·K KhuntiUNKNOWN SOLVE Study Group
Apr 21, 2012·Diabetes Care·Silvio E InzucchiUNKNOWN European Association for the Study of Diabetes (EASD)
Oct 30, 2013·BMC Family Practice·Hasliza Abu HassanKhairani Omar
Nov 26, 2013·American Heart Journal·Jennifer B GreenRury R Holman
Jan 21, 2015·Diabetes, Obesity & Metabolism·M A BethelUNKNOWN TECOS Executive Committee
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Jul 7, 2015·International Journal of Clinical Practice·C J NgC H Teo
Aug 8, 2015·Cardiovascular Diabetology·Sanjoy K PaulKamlesh Khunti
Oct 12, 2016·Primary Care Diabetes·Kamlesh Khunti, David Millar-Jones
Jun 29, 2017·Diabetes, Obesity & Metabolism·Manel Mata-CasesDídac Mauricio
Oct 21, 2017·Diabetes, Obesity & Metabolism·David Russell-JonesKamlesh Khunti
Citations
Apr 9, 2019·Circulation·Elisabetta PatornoSebastian Schneeweiss
Jul 6, 2020·European Journal of Heart Failure·Finlay A McAlisterUNKNOWN TECOS Study Group
Jun 11, 2020·Journal of Pharmaceutical Health Care and Sciences·Tomoyuki SaitoHiroyuki Daida
Jan 16, 2021·Antioxidants·Arokia Vijaya Anand MariadossMyeong-Hyeon Wang
Feb 20, 2021·Diabetes, Obesity & Metabolism·Marta BavieraFrancesco Giorgino
Oct 26, 2021·The Cochrane Database of Systematic Reviews·Takayoshi KanieJoey Sw Kwong